Exploring tumor stiffness and adhesion in gliomas using magnetic resonance elastography
Official title: Comprehensive Assessment of Tumor Stiffness and Adhesion in Glioma Using Magnetic Resonance Elastography: A Prospective Study
Run by Shengjing Hospital · NCT05990244 · Data updated 2026-11-12
This study is testing whether measuring the stiffness of glioma tumors with a special imaging technique can help doctors understand their characteristics better and improve treatment for patients.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Shengjing Hospital Academic / other |
| Locations | 1 site (Shenyang, Liaoning) |
| Status | Recruiting |
| Started | January 1, 2017 |
| Main results expected | July 1, 2026 |
| Study ends | July 1, 2027 |
| Registry record updated | December 2, 2025 |
| Trial ID | NCT05990244 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients scheduled for glioma resection surgery.
✕Probably not a fit
Patients with metallic implants, severe claustrophobia, or those who cannot tolerate MRE may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the relationship between tumor stiffness and adhesion in gliomas through the use of Magnetic Resonance Elastography (MRE). By employing preoperative MRE and intraoperative neuronavigation, the research aims to correlate tumor mechanical properties with molecular and genetic characteristics. Comprehensive molecular pathology analysis will follow tissue sample collection during surgery. The goal is to enhance clinical decision-making and personalize treatment approaches for glioma patients based on the findings.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic accuracy and personalized treatment strategies for glioma patients.
How similar studies have gone: Other studies utilizing MRE for tumor characterization have shown promising results, indicating potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. age older than 18 years 2. Karnofsky performance status higher than 60 3. with written informed consent 4. MRE performed within one week before surgery 5. tumor diameter \> 2 cm Exclusion Criteria: 1. previous treatment for glioma 2. inability to complete MRE due to intolerance (e.g., vibration-related discomfort or claustrophobia) 3. completed MRE with suboptimal wave image quality (e.g., motion artifacts or inad-equate wave amplitude) 4. failure to proceed with surgery after MRE 5. missing IDH results
Where it's running
-
Shengjing Hospital
Shenyang, Liaoning, China Recruiting
Study contacts
- Principal investigator: Yu Shi, MD — Shengjing Hospital
- Study coordinator: Yu Shi, MD
- Email: 18940259980@163.com
- Phone: +86 189 4025 9980
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
YN003 injection in glioma patients
This phase 1 study tests whether YN003 injected IV is safe and tolerable for adults with recurrent or progressive glioma, and to explore how the drug behaves in the body and any early signs of activity.
-
Brain connectome project in adults with brain glioma undergoing surgery
This registry collects MRI data and clinical information from adults with glioma to see how brain networks relate to surgery and recovery.
-
Proton vs. Photon Radiation for Certain Grade 2–3 Gliomas
This study tests whether proton therapy can better preserve thinking and memory than photon therapy for adults with IDH-mutated grade 2–3 gliomas who need radiation.
-
Connectome-guided network planning for brain tumor surgery in eloquent areas
This study tests whether using patient-specific brain network maps from diffusion MRI can help surgeons plan and guide brain tumor removal in eloquent areas.
-
AI-powered analysis of brain MRI to help glioma care
Doctors will use AI to study existing MRI scans and patient data from adults with glioma to see if it can help with non-invasive diagnosis and treatment planning.
-
Safusidenib in IDH1-mutant glioma after vorasidenib progression
This trial tests safusidenib in people with IDH1-mutant glioma who progressed on vorasidenib and did not need immediate chemo or radiation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.